A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Dana-Farber Cancer Institute
Acerta Pharma BV
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
University of Arizona
Ohio State University Comprehensive Cancer Center
City of Hope Medical Center
Tianjin Medical University Cancer Institute and Hospital
BeiGene
Incyte Corporation
PrECOG, LLC.
Janssen Research & Development, LLC
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
Miltenyi Biomedicine GmbH
Dana-Farber Cancer Institute
Eastern Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
InnoCare Pharma Inc.
Cyteir Therapeutics, Inc.
University of Wisconsin, Madison
University of Giessen
Ruijin Hospital
Medical University of Vienna
Ruijin Hospital
Washington University School of Medicine
Fate Therapeutics
Brown University
Fondazione Italiana Linfomi - ETS
TG Therapeutics, Inc.
Incyte Corporation
SWOG Cancer Research Network
SymBio Pharmaceuticals
Czech Lymphoma Study Group
Gilead Sciences
Samsung Medical Center
University of California, Davis
Wake Forest University Health Sciences
Lund University Hospital
Fondazione Italiana Linfomi - ETS
Teva Branded Pharmaceutical Products R&D, Inc.
Johannes Gutenberg University Mainz
University of Washington
French Innovative Leukemia Organisation
Jichi Medical University
Teva Branded Pharmaceutical Products R&D, Inc.
SymBio Pharmaceuticals
National Cancer Institute (NCI)
St. Bortolo Hospital